In this interview, Christian Roghi explores the manufacturing, quality control and regulatory challenges facing living medicines; from microbiome therapeutics to phage therapies and engineered bacteria, he reveals what is needed to bring these products to market at scale.
Alex Gauthier at Novartis reviews practical toxicological strategies for managing late-stage nitrosamine drug substance-related impurities (NDSRIs) while maintaining patient safety and development timelines.
Discover the key technologies, risk mitigation strategies and development considerations shaping modern pharmaceutical formulation — from early-stage selection through to commercial-scale manufacturing.
EPR Issue 2 includes articles on manufacturing, drug formulation, microbiology, downstream bioprocessing, and more.
Laverock Therapeutics appoints new leadership team as it prepares to advance its CAR-T programmes towards clinical development.
A weekly roundup of the latest regulatory updates affecting pharmaceutical development, manufacturing and commercialisation, from new guidance and legislative changes to significant medicine approvals.
Eli Lilly has secured approval for orforglipron in China, becoming the first company to bring an oral GLP-1 receptor agonist for weight management to the country’s market.
Matthew Durdy will step down in June 2027 after nearly 15 years with the organisation, including seven years as CEO, as the Board begins its search for a successor.
In this interview, Christian Roghi explores the manufacturing, quality control and regulatory challenges facing living medicines; from microbiome therapeutics to phage therapies and engineered bacteria, he reveals what is needed to bring these products to market at scale.
Jennifer Gattari of Pfizer CentreOne discusses how patient needs, evolving delivery formats and emerging manufacturing trends are shaping the pharmaceutical industry, from oral solid dose products to sterile injectables.